Frequency Therapeutics, Inc. FREQ
0.30 0.00 (+0.00%)
At closeNov 3, 2023, 4:00 PM EDT
0.28 Day range 0.32
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 0.50
Ratings (-1m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 1
- 2 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.35 | -0.38 – -0.33 | -0.55 | +36.4% | 0 | 0.0% | 2 |
| Next quarter | -0.29 | -0.35 – -0.23 | -0.49 | +40.8% | 0 | 0.0% | 2 |
| Current year | -1.55 | -1.70 – -1.40 | -2.33 | +33.5% | 0 | 0.0% | 2 |
| Next year | -1.14 | -1.45 – -0.83 | -1.55 | +26.5% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 25, 2023 | Baird | Downgrade | Outperform | Neutral |
| Feb 14, 2023 | Chardan Capital | Downgrade | Buy | Neutral |
| Feb 13, 2023 | Oppenheimer | Downgrade | Outperform | Perform |
| Feb 13, 2023 | Baird | Maintained | — | Outperform |
| Dec 7, 2022 | Chardan Capital | Initiated | — | Buy |
| Nov 1, 2022 | Baird | Initiated | — | Outperform |
| May 23, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Mar 22, 2022 | B. Riley Securities | Maintained | — | Buy |
| Sep 21, 2021 | Goldman Sachs | Downgrade | Buy | Neutral |
| Mar 23, 2021 | Oppenheimer | Maintained | — | Outperform |
| Jan 26, 2021 | JP Morgan | Upgrade | Neutral | Overweight |
| Jul 13, 2020 | Oppenheimer | Initiated | — | Outperform |
| May 17, 2020 | JP Morgan | Downgrade | Overweight | Neutral |
| Mar 26, 2020 | JP Morgan | Maintained | — | Overweight |
| Oct 27, 2019 | JP Morgan | Initiated | — | Overweight |
| Oct 27, 2019 | Cowen & Co. | Initiated | — | Outperform |
| Oct 27, 2019 | Goldman Sachs | Initiated | — | Buy |